Preclinical evaluation of SAR408701 demonstrated high binding specificity (KD = 0.5–2 nM) for CEACAM5, with potent dose-dependent antitumour activity in both in vitro and in vivo models, achieving 70–90% tumour growth inhibition in CEACAM5-expressing xenografts through its dual mechanism of antibody-mediated targeting and DM4-induced microtubule disruption [31]. This evidence concerns the gene CEACAM5 and neoplasm.